Patent ID: 8338444

Claim:
A drug product comprising a drug substance selected from the group consisting of: amorphous hydrocodone pamoate characterized by at least one method selected from the group consisting of: a differential scanning calorimeter thermogram of FIG. 10 ; an FTIR of FIG. 11 ; and an X-ray diffraction diffractogram of FIG. 12 ; polymorphic hydrocodone pamoate characterized by at least one method selected from the group consisting of: a differential scanning calorimeter thermogram of FIG. 13 ; an FTIR of FIG. 14 ; and an X-ray diffraction diffractogram of FIG. 15 ; amorphous oxycodone pamoate characterized by at least one method selected from the group consisting of: a differential scanning calorimetery thermogram of FIG. 1 ; an FTIR of FIG. 2 ; and an X-ray diffraction diffractogram of FIG. 3 ; polymorphic oxycodone pamoate characterized by at least one method selected from the group consisting of: a differential scanning calorimetery thermogram of FIG. 4 ; an FTIR of FIG. 5 ; and an X-ray diffraction diffractogram of FIG. 6 ; oxycodone xinafoate characterized by at least one method selected from the group consisting of: a differential scanning calorimetery thermogram of FIG. 7 ; an FTIR of FIG. 8 ; and an X-ray diffraction diffractogram of FIG. 9 ; amorphous morphine pamoate characterized by at least one method selected from the group consisting of: a differential scanning calorimetery thermogram of FIG. 28 ; an FTIR of FIG. 29 ; and an X-ray diffraction diffractogram of FIG. 30 ; polymorphic morphine pamoate characterized by at least one method selected from the group consisting of: a differential scanning calorimetery thermogram of FIG. 31 ; an FTIR of FIG. 32 ; and an X-ray diffraction diffractogram of FIG. 32 ; and morphine xinafoate characterized by at least one method selected from the group consisting of: a differential scanning calorimetery thermogram of FIG. 34 ; an FTIR of FIG. 35 ; an X-ray diffraction diffractogram of FIG. 36 ; hydrocodone xinafoate characterized by at least one method selected from the group consisting of: a differential scanning calorimetery thermogram of FIG. 16 ; an FTIR of FIG. 17 ; and X-ray diffraction diffractogram of FIG. 18 ; amorphous hydromorphone pamoate characterized by at least one method selected from the group consisting of: a differential scanning calorimetery thermogram of FIG. 19 ; an FTIR of FIG. 20 ; and X-ray diffraction diffractogram of FIG. 21 ; polymorphic hydromorphone pamoate characterized by at least one method selected from the group consisting of: a differential scanning calorimetery thermogram of FIG. 22 ; an FTIR of FIG. 23 ; and X-ray diffraction diffractogram of FIG. 24 ; and hydromorphone xinafoate characterized by at least one method selected from the group consisting of: a differential scanning calorimetery thermogram of FIG. 25 ; an FTIR of FIG. 26 ; and X-ray diffraction diffractogram of FIG. 27 ; wherein said drug substance is bioavailable in the human gastrointestinal tract at a predetermined rate and said rate is not increased by ingestion of alcohol.